Безопасность и эффективность ромиплостима в лечении тромбоцитопении у детей с синдромом Вискотта–Олдрича: результаты ретроспективного исследования

синдром Вискотта–Олдрича, ромиплостим, тромбоцитопения, геморрагический синдром

1. Sullivan K.E., Mullen C.A., Blaese R.M., Winkelstein J.A. A multiinstitutional survey of the Wiskott–Aldrich syndrome. J Pediatr 1994; 125: 876–885. DOI: 10.1016/s0022-3476(05)82002-5

2. Moratto D., Giliani S., Bonfim C., Mazzolari E., Fischer A., Ochs H.D., et al. Long-term outcome and lineage-specific chimerism in 194 patients with WiskottAldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011; 118: 1675–84. DOI: 10.1182/blood-2010-11-319376

3. Balashov D., Laberko A., Shcherbina A., Trakhtman P., Abramov D., Gutovskaya E., et al. Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRab+ and CD19+ Cell-Depleted Stem Cell Transplantation in Patients with Wiskott–Aldrich Syndrome. Biol Blood Marrow Transplant 2018; 24 (7): 1432–40. DOI: 10.1016/j.bbmt.2018.03.006

4. Ferrua F., Marangoni F., Aiuti A., Roncarolo M.G. Gene therapy for WiskottAldrich syndrome: History, new vectors, future directions. J Allergy Clin Immunol 2020; 146 (2): 262–5. DOI: 10.1016/j.jaci.2020.06.018

5. Rivers E., Worth A., Thrasher A.J., Burns S.O. Bleeding and splenectomy in Wiskott–Aldrich syndrome: A single-centre experience. J Allergy Clin Immunol Pract 2019; 7: 1042–4. DOI: 10.1016/j.jaip.2018.07.009

6. Lengline E., Drenou B., Peterlin P., Tournilhac O., Abraham J., Berceanu A., et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica 2018; 103 (2): 212–20. DOI: 10.3324/haematol.2017.176339

7. Giordano P., Lassandro G., Barone A., Cesaro S., Fotzi I., Giona F., et al. Use of Eltrombopag in Children with Chronic Immune Thrombocytopenia (ITP): A Real Life Retrospective Multicenter Experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Front Med (Lausanne) 2020; 7: 66. DOI: 10.3389/fmed.2020.00066

8. Bussel J.B., de Miguel P.G., Despotovic J.M., Grainger J.D., Sevilla J., Blanchette V.S., et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2015; 2 (8): e315–25. DOI: 10.1016/S2352-3026(15)00114-3

9. Townsley D.M., Scheinberg P., Winkler T., Desmond R., Dumitriu B., Rios O., et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med 2017; 376 (16): 1540–50. DOI: 10.1056/NEJMoa1613878

10. Erickson-Miller C.L., Delorme E., Tian S.S., Hopson C.B., Landis A.J., Valoret E.I., et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009; 27 (2): 424–30. DOI: 10.1634/stemcells.2008-0366

11. Wang B., Nichol J.L., Sullivan J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76 (6): 628–38. DOI: 10.1016/j.clpt.2004.08.010

12. Al-Samkari H., Kuter D.J. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol 2019; 10: 2040620719841735. DOI: 10.1177/2040620719841735

13. Gerrits A.J., Leven E.A., Frelinger A.L. III, Brigstocke S.L., Berny-Lang M.A., Mitchell W.B., et al. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015; 126 (10): 1367–78. DOI: 10.1182/blood-2014-09-602573

14. Zaninetti C., Gresele P., Bertomoro A., Klersy C., De Candia E., Veneri D., et al. Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial. Haematologica 2020; 105: 820–8. DOI: 10.3324/haematol.2019.223966

15. Першин Д.Е., Лодоева О.Б., Фадеева М.С., Мерсиянова И.В., Хорева А.Л., Владимиров И.С. и др. Разработка метода диагностики синдрома Вискотта–Олдрича путем оценки экспрессии белка WASP с использованием проточной цитофлуориметрии. Вопросы гематологии/онкологии и

16. иммунопатологии в педиатрии 2020; 19 (2): 141-151. DOI: 10.24287/1726-1708-2020-19-2-141-151

17. Zhu Q., Watanabe C., Liu T., Hollenbaugh D., Blaese R.M., Kanner S.B., et al. Wiskott–Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood 1997; 90: 2680–9.

18. Kaufman R.M., Djulbegovic B., Gernsheimer T., Kleinman S., Tinmouth A.T., Capocelli K.E., et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015; 162 (3): 205–13. DOI: 10.7326/M14-1589

19. Moiseeva A., Mersiyanova I., Hachatrian L., Karelin A., Kovrigin S., Pershin D., et al. Wiskott–Aldrich syndrome in a girl with skewed X-chromosome inactivation. ESID 2018 Meeting abstracts.

20. Saleh M.N., Bussel J.B., Cheng G., Meyer O., Bailey C.K., Arning M., et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open- label EXTEND study. Blood 2013; 121: 537–45. DOI: 10.1182/blood-2012-04-425512

21. Cheng G., Saleh M.N., Marcher C., Vasey S., Mayer B., Aivado M., et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377 (9763): 393–402. DOI: 10.1016/S0140-6736(10)60959-2

22. Grace R.F., Shimano K.A., Bhat R., Neunert C., Bussel J.B., Klaassen R.J., et al. Second-line treatments in children with immune thrombocytopenia: effect on platelet count and patient-centered outcomes. Am J Hematol 2019; 94: 741–50. DOI: 10.1002/ajh.25479

23. Kajiwara M., Nonoyama S., Eguchi M., Morio T., Imai K., Okawa H., et al. WASP is involved in proliferation and differentiation of human haemopoietic progenitors in vitro. Br J Haematol 1999; 107 (2): 254–62. DOI: 10.1046/j.1365-2141.1999.01694.x

24. Sabri S., Foudi A., Boukour S., Franc B., Charrier S., Jandrot-Perrus M., et al. Deficiency in the Wiskott–Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood 2006; 108: 134–40. DOI: 10.1182/blood-2005-03-1219

25. Ingrungruanglert P., Amarinthnukrowh P., Rungsiwiwut R., Maneesri-le Grand S., Sosothikul D., Suphapeetiporn K., et al. Wiskott–Aldrich syndrome iPS cells produce megakaryocytes with defects in cytoskeletal rearrangement and proplatelet formation. Thromb Haemost 2015; 113: 792–805. DOI: 10.1160/TH14-06-0503

26. Gröttum K.A., Hovig T., Holmsen H., Abrahamsen A.F., Jeremic M., Seip M. Wiskott–Aldrich syndrome: qualitative platelet defects and short platelet survival. Br J Haematol 1969; 17: 373–88. DOI: 10.1111/j.1365-2141.1969.tb01383.x

27. Shcherbina A., Rosen F.S., Remold-O'Donnell E. Pathological events in platelets of Wiskott–Aldrich syndrome patients. Br

28. J Haematol 1999; 106: 875–883. DOI: 10.1046/j.1365-2141.1999.01637.x

29. Shcherbina A., Miki H., Kenney D.M., Rosen F.S., Takenawa T., Remold-O’Donnell E. WASP and N-WASP in human platelets differ in sensitivity to protease calpain. Blood 2001; 98: 2988–91. DOI: 10.1182/blood.v98.10.2988

30. Prislovsky A., Marathe B., Hosni A., Bolen A.L., Nimmerjahn F., Jackson C.W., et al. Rapid platelet turnover in WASP(–) mice correlates with increased ex vivo phagocytosis of opsonized WASP(–) platelets. Exp Hematol 2008; 36: 609–23. DOI: 10.1016/j.exphem.2007.12.019

31. Prislovsky A., Zeng X., Sokolic R.A., Garabedian E.N., Anur P., Candotti F., et al. Platelets from WAS patients show an increased susceptibility to ex vivo phagocytosis. Platelets 2013; 24: 288–96. DOI: 10.3109/09537104.2012.693991

32. Prislovsky A., Strom T.S. Increased uptake by splenic red pulp macrophages contributes to rapid platelet turnover in WASP– mice. Exp Hematol 2013; 41: 789–98. DOI: 10.1016/j.exphem.2013.05.003

33. Obydennyi S., Artemenko E., Sveshnikova A., Ignatova A.A., Varlamova T.V., Gambaryan S. et al. Mechanisms of increased mitochondria-dependent necrosis In Wiskott–Aldrich syndrome platelets. Haematologica 2020; 105: 1095–106. DOI: 10.3324/haematol.2018.214460

34. Bussel J.B., Kuter D.J., Pullarkat V., Lyons R.M., Guo M., Nichol J.L. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161–71. DOI: 10.1182/blood-2008-04-150078

35. Al-Samkari H., Kuter D.J. Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. Semin Thromb Hemost 2020; 46 (3): 275–88. DOI: 10.1055/s-0039-1700512

36. Kuter D.J., Rummel M., Boccia R., Macik B.G., Pabinger I., Selleslag D., et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363 (20): 1889–99. DOI: 10.1056/NEJMoa1002625

37. Bussel J.B., Cheng G., Saleh M.N., Psaila B., Kovaleva L., Meddeb B., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357 (22): 2237–47. DOI: 10.1056/NEJMoa073275

38. Gernsheimer T.B., George J.N., Aledort L.M., Tarantino M.D., Sunkara U., Matthew Guo D., et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010; 8 (6): 1372–82. DOI: 10.1111/j.1538-7836.2010.03830.x

39. Al-Samkari H., Kuter D.J. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol 2018; 93 (12): 1501–8. DOI: 10.1002/ajh.25275